Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Dose-escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of FL115 Injection Administered Subcutaneously as Monotherapy in Participants With Advanced Solid Tumours

NCT07785193 is registered in ClinicalTrials.gov with Suzhou Forlong Biotechnology Co., Ltd as lead sponsor.

NCT NCT07785193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07785193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Dose-escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of FL115 Injection Administered Subcutaneously as Monotherapy in Participants With Advanced Solid Tumours
Lead sponsor
Suzhou Forlong Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours